Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells

Cancer Biology and Therapy

Volumn 6, Issue 7, 2007, Pages 1036-1043

  Kamata, Shigeyuki ^a   Kishimoto, Takashi ^a,b   Kobayashi, Soichi ^a   Miyazaki, Masaru ^a   Ishikura, Hiroshi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

AFP; Apoptosis; Chemotherapy; Cisplatin; Gastric cancer; Mammalian target of rapamycin (mTOR); Rapamycin

Indexed keywords

CISPLATIN; FLUOROURACIL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOMYCIN C; PACLITAXEL; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN CGC; CELL STRAIN FU97; CELL STRAIN GCIY; CELL STRAIN TAKIGAWA; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STOMACH CANCER;

EID: 42449159315     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.7.4253     Document Type: Article

References (49)

1. Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, Matsumoto Y. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002; 19:359-65.
2. Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 1992; 87:321-5.
3. Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients. Oncology 2003; 65:95-101.
4. Ishikura H, Kishimoto T, Andachi H, Kakuta Y, Yoshiki T. Gastrointestinal hepatoid adenocarcinoma: Venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Histopathology 1997; 31:47-54.
5. Chang YC, Nagasue N, Abe S, Kohno H, Kumar DD, Nakamura T. Alpha Fetoprotein producing early gastric cancer with liver metastasis: Report of three cases. Gut 1991; 32:542-5.
6. Kubota O, Suzuki T, Takahashi T, Kosukegawa M, Yamashita K, Mori S, Mochizuki K, Futami H, Takai T, Shamoto M. A case of AFP-producing early gastric carcinoma with rapid growth liver metastasis. Hepatogastroenterology 2001; 48:1206-8.
7. Giustozzi G, Goracci G, Bufalari A, Lauro A, Cirocchi R, Boselli C, Bartoli A, Monacelli M, Giansanti M, Moggi L. Hepatoid carcinoma of the stomach: Is it still an unusual anatomo-clinical entity? Six cases-report. J Exp Clin Cancer Res 1999; 18:571-3.
8. Chiba N, Yoshioka T, Sakayori M, Mikami Y, Miyazaki S, Akiyama S, Otsuka K, Yamaura G, Shibata H, Kato S, Kato S, Ishioka C. AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/ CDDP: A case report. Anticancer Res 2005; 25:2965-8.
9. Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 2000; 19:3021-31.
10. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005; 4:25-35.
11. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-89.
12. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003; 11:895-904.
13. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8.
14. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-302.
15. Mendez R, Myers Jr MG, White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol 1996; 16:2857-64.
16. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998; 12:502-13.
17. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-262.
18. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377:441-6.
19. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence Jr JC, Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277:99-101.
20. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004; 64:5659-63.
21. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98:10320-5.
22. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005; 117:376-80.
23. Nozue M, Nishida M, Todoroki T, Isawaki T. Establishment and characterization of a human scirrhous-type of gastric cancer cell line, GCIY, producing CA19-9. Hum Cell 1991; 4:71-5, (article in Japanese).
24. Matsuda M, Watanabe A, Sawada H, Yamada Y, Nakano H, Iwai M, Iwai Y. Establishment of an α-fetoprotein-producing cell line derived from gastric cancer. In Vitro Cell Dev Biol Anim 1999; 35:555-7.
25. Sekiguchi M, Fujii Y, Saito A, Suzuki T, Shiroko Y, Nakamura H, Hasumi K. Alpha-fetoprot ein-producing gastric carcinoma: Biological properties of a cultured cell line. J Gastroenterol 1995; 30:589-98.
26. Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, Wallance J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998; 77:1-10.
27. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747-59.
28. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273:14424-9.
29. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10:8421-5.
30. Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, Han JW. Constitutive activation of p70S6k in cancer cells. Arch Pharm Res 2002; 25:685-90.
31. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T, Eguchi K. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002; 8:3046-53.
32. Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, Fando JL. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32:633-42.
33. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975; 28:721-6.
34. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273:239-42.
35. Grove JR, Banerjee P, Balasubramanyam A, Coffer PJ, Price DJ, Avruch J, Woodgett JR. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 1991; 11:5541-50.
36. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence Jr JC, Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5-prime-cap function. Nature 1994; 371:762-7.
37. Rousseau D, Gingras AC, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996; 13:2415-20.
38. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852-64.
39. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-19.
40. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399:483-7.
41. Desbiens KM, Deschesnes RG, Labrie MM, Desfosses Y, Lambert H, Landry J, Bellmann K. c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade. Biochem J 2003; 372:631-41.
42. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: Implication of AKT2 in chemoresistance. J Biol Chem 2003; 278:23432-40.
43. Huang S, Shu L, Easton J, Harwood FC, Germain GS, Ichijo H, Houghton PJ. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 2004; 279:36490-6.
44. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
45. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Hsieh CY, Pu YS. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 2000; 20:3221-5.
46. Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 1996; 68:372-27.
47. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-35.
48. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64:252-61.
49. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-18.